OPKO Health Announces New Listing on Tel Aviv Stock Exchange

  OPKO Health Announces New Listing on Tel Aviv Stock Exchange

—Shares already listed on NYSE and will also list on the TASE beginning August
                         21— under Ticker Symbol OPK

Business Wire

MIAMI & TEL AVIV, Israel -- August 19, 2013

OPKO Health, Inc. (NYSE: OPK), a multi-national biopharmaceutical and
diagnostics company, today announced that the Tel-Aviv Stock Exchange (“TASE”)
has approved the new listing of OPKO’s common stock on the TASE beginning on
August 21, 2013, under the ticker symbol OPK. OPKO’s common stock will
thereafter be listed on both the NYSE in the United States and the TASE in
Israel. Based on OPKO’s market capitalization, OPKO expects its shares to be
included in the TA-25 Index (TA-25), the TASE flagship index which tracks the
share prices of the 25 companies with the highest market capitalization on the
exchange.

“We are very pleased to welcome OPKO, a biopharmaceutical and diagnostic
company which is active around the world, to the Tel-Aviv Stock Exchange, and
its entry into the leading indexes of TASE,” said Ester Levanon, CEO of the
Tel-Aviv Stock Exchange. “Over the past few years TASE has become a center for
biomed companies. The registration of OPKO on TASE demonstrates a vote of
confidence in the Israeli stock market and the leading position of the biomed
sector on TASE. By virtue of its dual listing, OPKO will enjoy significant
advantages, including exposure to Israeli investors, expanded trading hours,
investment by way of index-based instruments, exchange traded notes and funds
and specialized funds, and easy access to institutional and private investors
and emerging global companies.”

“We are pleased to start trading on the TASE with this dual listing and to
join Israel’s top companies as part of the TA-25 index,” commented Dr. Phillip
Frost, OPKO’s Chairman and Chief Executive Officer. “We believe that this step
will expand our exposure to the Israeli investment community and will increase
the interest in OPKO among Israel’s large and sophisticated institutional
investors. We already have a significant presence in Israel through our
ownership of FineTech Pharmaceuticals Ltd, based in Nesher, Israel, which is
engaged in the development and production of high-value, high-potency
specialty active pharmaceutical ingredients, and a controlling interest in
Sci-Vac Ltd, which manufactures and sells a third-generation hepatitis B
vaccine produced in a state of the art biologics manufacturing facility in
Rehovot, Israel. We expect that Israel will become OPKO’s biotechnology R&D
global center upon completion of our pending acquisition of PROLOR Biotech,
Inc., a biopharmaceutical company based in Nes Ziona, Israel that is applying
unique technologies to develop and commercialize longer-acting proprietary
versions of already approved therapeutic proteins.”

OPKO will remain subject to the rules and regulations of the NYSE and of the
U.S. Securities and Exchange Commission. Trading on the TASE occurs on Sunday
from 9:45 AM to 4:30 PM Israel time and on Monday through Thursday from 9:45
AM to 5:30 PM Israel time, except on TASE trading holidays. Through the
amendment to Israel’s Securities Law 5728-1968, that took effect in October
2000, U.S.-listed companies may dual-list on the TASE without any additional
regulatory requirements. TASE links to the U.S. markets via a direct link to
DTC, a subsidiary of the Depository Trust & Clearing Corporation, which
facilitates the trading of dually-listed securities.

ABOUTOPKO HEALTH, INC.

OPKO is a multinational biopharmaceutical and diagnostics company that seeks
to establish industry leading positions in large, rapidly growing markets by
leveraging its discovery, development and commercialization expertise and
novel and proprietary technologies. For more information, visit
http://www.opko.com.

SAFE HARBOR STATEMENT

This press release includes forward looking statements, within the meaning of
the Private Securities Litigation Reform Act of 1995, which are subject to
risk and uncertainties that could cause actual results to differ materially
from those anticipated. Such statements may relate to OPKO’s plans, objectives
and expected financial and operating results, including statements regarding
our ability to expand our exposure to the Israeli investment community and
increase interest in OPKO among Israel’s large and sophisticated institutional
investors. The words "may," "could," "would," “will,” "believe," "anticipate,"
"estimate," "expect," "intend," "plan," and similar expressions or variations
thereof are intended to identify forward-looking statements. Investors are
cautioned that any such forward-looking statements are not guarantees of
future performance and involve risks and uncertainties, many of which are
beyond OPKO’s ability to control. The risks and uncertainties that may affect
forward looking statements include, but are not limited to: currency
fluctuations, global economic and political conditions, marketing demand for
OPKO’s products and services, long sales cycles, new product development,
assimilating future acquisitions, maintaining relationships with customers and
partners, and increased competition, as well as the risk we may not complete
the acquisition of PROLOR Biotech, Inc. For more details about the risks and
uncertainties related to OPKO’s business, refer to OPKO’s filings with the
Securities and Exchange Commission. OPKO undertakes no obligation to publicly
update or revise any forward looking statements, whether as a result of new
information, future events or otherwise.

Contact:

OPKO Heath, Inc.
Steve D. Rubin
Executive Vice President – Administration
or
Juan F. Rodrigez
Chief Financial Officer
+1-305-575-4100
 
Press spacebar to pause and continue. Press esc to stop.